智通财经网·2025-12-24 13:55Core Viewpoint - Sanofi has agreed to acquire Dynavax Technologies for approximately $2.2 billion to expand its vaccine product line, primarily focused on flu vaccines, with a cash offer of $15.50 per share, representing a 39% premium over Dynavax's closing price on Tuesday [1] Group 1: Acquisition Details - The acquisition price is set at about $2.2 billion [1] - Sanofi will pay $15.50 in cash per share for Dynavax, which is a 39% premium over the previous closing price [1] - The deal aims to enhance Sanofi's market presence in adult vaccination [1] Group 2: Product Portfolio Impact - Through this acquisition, Sanofi will gain access to an already marketed hepatitis B vaccine and an experimental shingles vaccine currently in early human trials [1] - This move will strengthen Sanofi's existing vaccine portfolio, which includes products for flu, respiratory syncytial virus, meningitis, and whooping cough [1]